High-protein high-energy feeds are estimated at 46.4% of formulation demand in 2026, with moderate burns at 56.1% and enteral tube feeds at 47.4%. Purchasing follows metabolic need and feeding access, but evidence thresholds, tolerance, and care transitions determine which products stay on formulary.